+

WO2003038045A3 - Gene d'acide phosphatase (acp1) constituant un locus de susceptibilite a l'hyperlipidemie - Google Patents

Gene d'acide phosphatase (acp1) constituant un locus de susceptibilite a l'hyperlipidemie Download PDF

Info

Publication number
WO2003038045A3
WO2003038045A3 PCT/US2002/034500 US0234500W WO03038045A3 WO 2003038045 A3 WO2003038045 A3 WO 2003038045A3 US 0234500 W US0234500 W US 0234500W WO 03038045 A3 WO03038045 A3 WO 03038045A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperlipidemia
acp1
gene
acid phosphatase
susceptibility locus
Prior art date
Application number
PCT/US2002/034500
Other languages
English (en)
Other versions
WO2003038045A2 (fr
Inventor
David E Comings
James P Macmurray
Nunzio Bottini
Original Assignee
Hope City
David E Comings
James P Macmurray
Nunzio Bottini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City, David E Comings, James P Macmurray, Nunzio Bottini filed Critical Hope City
Priority to AU2002356862A priority Critical patent/AU2002356862A1/en
Priority to US10/493,881 priority patent/US20050055732A1/en
Publication of WO2003038045A2 publication Critical patent/WO2003038045A2/fr
Publication of WO2003038045A3 publication Critical patent/WO2003038045A3/fr
Priority to US12/056,624 priority patent/US20080241928A1/en
Priority to US12/835,678 priority patent/US8034794B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne l'allèle ACP1*A permettant de diagnostiquer la prédisposition d'un sujet humain à l'hyperlipidémie, en particulier l'hyperlipidémie associée au syndrome métabolique, de traiter ou de prévenir l'apparition de l'hyperlipidémie et du syndrome métabolique, et de cribler et d'identifier des médicaments adaptés pour être utilisés dans le traitement ou la prévention de l'hyperlipidémie, en particulier l'hyperlipidémie associée au syndrome métabolique. L'invention concerne également des kits de diagnostic.
PCT/US2002/034500 2001-10-29 2002-10-29 Gene d'acide phosphatase (acp1) constituant un locus de susceptibilite a l'hyperlipidemie WO2003038045A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002356862A AU2002356862A1 (en) 2001-10-29 2002-10-29 Acid phosphatase (acp1) gene as a susceptibility locus for hyperlipidemia
US10/493,881 US20050055732A1 (en) 2001-10-29 2002-10-29 Acid phosphatase (acp1)gene as a susceptibility locus for hyperlipidemia
US12/056,624 US20080241928A1 (en) 2001-10-29 2008-03-27 Methods and compositions for acid phosphatase-1 gene inhibition
US12/835,678 US8034794B2 (en) 2001-10-29 2010-07-13 Methods and compositions for acid phosphatase-1 gene inhibition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33069301P 2001-10-29 2001-10-29
US60/330,693 2001-10-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10493881 A-371-Of-International 2002-10-29
US12/056,624 Continuation US20080241928A1 (en) 2001-10-29 2008-03-27 Methods and compositions for acid phosphatase-1 gene inhibition

Publications (2)

Publication Number Publication Date
WO2003038045A2 WO2003038045A2 (fr) 2003-05-08
WO2003038045A3 true WO2003038045A3 (fr) 2003-10-30

Family

ID=23290894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034500 WO2003038045A2 (fr) 2001-10-29 2002-10-29 Gene d'acide phosphatase (acp1) constituant un locus de susceptibilite a l'hyperlipidemie

Country Status (3)

Country Link
US (3) US20050055732A1 (fr)
AU (1) AU2002356862A1 (fr)
WO (1) WO2003038045A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609180A1 (fr) * 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Compositions et utilisations dans la lmw-ptpase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2003099313A1 (fr) * 2002-05-23 2003-12-04 Purdue Research Foundation Tyrosine phosphatase de faible poids moleculaire (lmw-ptp) servant de cible a usage diagnostique et therapeutique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOTTINI E. ET AL.: "ACP1 and human adaptability 1. Association with comon diseases: a case-control study", HUM. GENET., vol. 96, 1995, pages 629 - 637, XP002967829 *
BOTTINI N. ET AL.: "Low-molecular weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms", ARCH. IMMUNOL. THERAP. EXPERIMENT., vol. 50, 2002, pages 95 - 104, XP002967830 *
SENSABAUGH G.F.A. ET AL.: "TaqI site identifies the *A allele at the ACP1 locus", HUMAN MOLECULAR GENETICS, vol. 2, 1993, pages 1079, XP002967831 *

Also Published As

Publication number Publication date
US20050055732A1 (en) 2005-03-10
WO2003038045A2 (fr) 2003-05-08
AU2002356862A1 (en) 2003-05-12
US20100280103A1 (en) 2010-11-04
US8034794B2 (en) 2011-10-11
US20080241928A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU5166198A (en) Opaque reaction matrix for the analysis of whole blood
AU2815900A (en) Clinical and diagnostic database
EP1690535A3 (fr) Utilisation therapeutique d'un précurseur d'oxide nitric
WO2003085095A3 (fr) Nouveaux genes exprimes
WO2006063704A3 (fr) Polymorphisme a simple nucleotide (snp)
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO1998019167A3 (fr) Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule
AU5252698A (en) Therapeutic compositions and methods and diagnostic assays for type ii diabetes involving hnf-1
WO2000018912A3 (fr) Genes et proteines de cassette de liaison avec atp, destines au diagnostic et au traitement de desordres lipidiques et maladies inflammatoires
WO2003102216A3 (fr) Systemes multiplexes conçus pour le sequençage d'acide nucleique
WO2001020031A3 (fr) Polymorphismes dans un gene klotho
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2000066782A3 (fr) Methode pour diagnostiquer le diabete sucre sur la base d'une charge de mutation
CA2251744A1 (fr) Procedes pour identifier la predisposition a l'osteoarthrose par un genotype recepteur de la vitamine d
AU9019198A (en) Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
CA2315218A1 (fr) Analyse de la predisposition a des pathologies specifiques sur la base du polymorphisme du gene de la tripsine protease des voies aeriennes humaines
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
WO2003038045A3 (fr) Gene d'acide phosphatase (acp1) constituant un locus de susceptibilite a l'hyperlipidemie
WO2001020026A3 (fr) Polymorphismes du gene humain hpxr et leur utilisation dans des applications diagnostiques et therapeutiques
CA2296178A1 (fr) Npt2b de l'intestin humain
WO2006063703A3 (fr) Polymorphisme a simple nucleotide (snp)
WO2003025198A3 (fr) Polymorphismes regulateurs d'un nucleotide simple et procedes associes
AU1331701A (en) Screening for disease susceptibility by genotyping the ccr5 and ccr2 genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10493881

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载